News
HOME > Latest News
Insumate® Patented Sequence mcIRBP-19 Transcends Metabolic Medicine
2020-09-15

2020-09-08 21:26Economic Daily News Tsao Sung-ching

Insumate® Patented Sequence mcIRBP-19 Transcends Metabolic Medicine.
Source: Greenyn Biotechnology

The contemporary lifestyle that consists of delicate foods and few exercises has resulted in numerous diseases of affluence that became the major challenge for global public health.
The International Diabetes Federation announced a shocking piece of data at the end of 2019 that there are over 460 million diabetic patients in the world, which costs USD$760 billion in medical expenditure each year, and 42 million deaths by diabetes or complications each year.
Diabetes has been one of the top 10 causes of death in Taiwan for 10 consecutive years that accounts for 23 million patients in the country. According to the statistics of the Ministry of Health and Welfare, diabetes occupied almost NTD$30 billion in the expense of healthcare during 2018, which is the second highest contributing factor to the exorbitant expenditure, making it a heavy burden on the society.
Greenyn Biotechnology has joined hands with institutions including the Chung Shan Medical University Hospital on completing two clinical trials of adjuvant therapy on diabetes that are approved by the review of IRB, with remarkable results that are able to develop functional foods for diabetic patients.
Doctor Yang Yi-tien of Chung Shan Medical University Hospital also publicly announced the random and double blinding clinical studies, with clinical results being submitted to international journals at the moment.
Doctor Hsu Pang-kuei commented that Greenyn Biotechnology and academic institutions took more than 10 years in the study of the “Insumate® Patented Sequence mcIRBP-19”, and the precious active ingredients require designated and patented processes as well as excellent production management in order to achieve the optimal effect of clinical trials.
Greenyn Biotechnology expressed that the Insumate® has been published by multiple international SCI authoritative journals, as well as received 19 multinational patents, and the recognition of the top 3 global invention awards.


Doctor Yang Yi-tien (middle) of Chung Shan Medical University Hospital announced the random and double blinding clinical studies.
Source: Greenyn Biotechnology

© 2015 Greenyn Biotechnology Co.,Ltd. All Rights Reserved │ WEB DESIGN BY MOONLIGHT